Lion Point Capital LP Has $783,000 Position in Benitec Biopharma Inc. (NASDAQ:BNTC)

Lion Point Capital LP boosted its stake in Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) by 59.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 62,000 shares of the biotechnology company's stock after buying an additional 23,000 shares during the period. Benitec Biopharma accounts for approximately 4.1% of Lion Point Capital LP's investment portfolio, making the stock its 10th largest holding. Lion Point Capital LP owned 0.27% of Benitec Biopharma worth $783,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Ameriprise Financial Inc. boosted its position in shares of Benitec Biopharma by 138.4% in the 4th quarter. Ameriprise Financial Inc. now owns 35,476 shares of the biotechnology company's stock valued at $448,000 after purchasing an additional 20,597 shares during the period. 683 Capital Management LLC bought a new position in shares of Benitec Biopharma in the 4th quarter valued at approximately $452,000. Northern Trust Corp raised its stake in shares of Benitec Biopharma by 54.2% in the 4th quarter. Northern Trust Corp now owns 38,200 shares of the biotechnology company's stock valued at $482,000 after acquiring an additional 13,425 shares in the last quarter. MYDA Advisors LLC acquired a new stake in Benitec Biopharma in the 4th quarter valued at approximately $632,000. Finally, Geode Capital Management LLC grew its holdings in Benitec Biopharma by 134.7% in the 4th quarter. Geode Capital Management LLC now owns 197,096 shares of the biotechnology company's stock valued at $2,490,000 after buying an additional 113,109 shares during the last quarter. 52.19% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BNTC has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $28.00 target price on shares of Benitec Biopharma in a report on Monday, March 24th. JMP Securities reaffirmed a "market outperform" rating and issued a $20.00 target price on shares of Benitec Biopharma in a report on Thursday. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Benitec Biopharma presently has a consensus rating of "Buy" and an average target price of $24.71.

Insiders Place Their Bets

In other news, Director Suvretta Capital Management, L bought 900,000 shares of the company's stock in a transaction dated Wednesday, March 26th. The stock was bought at an average price of $13.00 per share, for a total transaction of $11,700,000.00. Following the completion of the transaction, the director now directly owns 8,793,245 shares in the company, valued at $114,312,185. The trade was a 11.40% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 1.30% of the company's stock.

Benitec Biopharma Stock Performance

Benitec Biopharma stock traded up $0.10 on Friday, reaching $13.60. The company's stock had a trading volume of 27,494 shares, compared to its average volume of 41,067. The company has a market cap of $348.16 million, a price-to-earnings ratio of -9.01 and a beta of 0.34. The business's fifty day moving average price is $13.68 and its 200 day moving average price is $12.03. Benitec Biopharma Inc. has a twelve month low of $5.74 and a twelve month high of $16.90.

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.36) by $0.12. As a group, equities analysts forecast that Benitec Biopharma Inc. will post -1.48 earnings per share for the current year.

Benitec Biopharma Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.